East Sussex Healthcare
NHS Trust

Eastbourne District General Hospital
Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FOI REF: 26/829

26th November 2026

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

1. **How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction?**

   48.

2. **How many patients were treated in the past 3 months for gastric cancer (any stage) with:**

   - **CAPOX (Capecitabine with Oxaliplatin)** 3
   - **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)** 0
   - **Lonsurf (Trifluridine - tipiracil)** 0
   - **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 0
   - **Nivolumab (300mg or 600mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 0
   - **Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 0
   - **Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 0
   - **Zolbetuximab (Vyloy)** 0

- **Any other systemic anti-cancer therapy** 5

- **Palliative care only**

  East Sussex Healthcare NHS Trust does not centrally record patients being treated for palliative care only. To enable the Trust to provide this information will require a manual review of patients' notes to establish if we hold this information, and discussing each patient with individual clinicians, which we estimate would take in excess of 18 hours. We are therefore applying Section 12(1) to this part of your request.

  Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

- **Trastuzumab in combination with cisplatin and capecitabine (or 5-fluorouracil)** 2

- **Taxanes (e.g. docetaxel, paclitaxel)** 1

- **Irinotecan Chemotherapy** 0

3. **How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with:**

- **CAPOX (Capecitabine with Oxaliplatin)** 11

- **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)** 1

- **Lonsurf (Trifluridine - tipiracil)** 0

- **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 0

- **Nivolumab (300mg or 600mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 0

- **Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 0

- **Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 4

- **Zolbetuximab (Vyloy)** 0

- **Any other systemic anti-cancer therapy** 14

- **Palliative care only**

  East Sussex Healthcare NHS Trust does not centrally record patients being treated for palliative care only. To enable the Trust to provide this information will require a manual review of patients' notes to establish if we hold this information, and discussing each patient with individual clinicians, which we estimate would take in excess of 18 hours. We are therefore applying Section 12(1) to this part of your request.

  Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

- **Trastuzumab in combination with cisplatin and capecitabine (or 5-fluorouracil)** 0

- **Taxanes (e.g. docetaxel, paclitaxel)** 3

- **Irinotecan Chemotherapy** 0

4. Does your Organisation provide treatment for Oesophagael squamous cell carcinoma? If not, to which location do you refer said patients

Yes.

Please note, if treatment is not provided within your organisation please ignore the below questions

5. How many patients have received treatment for Oesophagael squamous cell carcinoma in the past 3 months?

5.

5a. How many of those patients have received treatment with the following treatments?

- **Pembrolizumab (infusion or injection) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 0

- **Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 4

- **Nivolumab (infusion or injection) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 1

- **Nivolumab (300mg or 600mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** 0

- **Any other systemic anti-cancer therapy** 0

- **Palliative care only**

  East Sussex Healthcare NHS Trust does not centrally record patients being treated for palliative care only. To enable the Trust to provide this information will require a manual review of patients' notes to establish if we hold this information, and discussing each patient with individual clinicians, which we estimate would take in excess of 18 hours. We are therefore applying Section 12(1) to this part of your request.

  Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

6. How many patients received treatment for recurrent oesophagael squamous cell carcinoma?

3.

6a. How many of these patients received the following treatments?

- **Nivolumab monotherapy (Infusion or Injection) (following previous platinum- and fluoropyrimidine-based chemotherapy)** 0

- **Nivolumab (300mg or 600mg solution for injection only) (following previous platinum- and fluoropyrimidine-based chemotherapy)** 0

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an

internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm